WO2007108749A8 - Chimeric constructs between cancer-homing peptides and cell-penetrating peptides coupled to anticancer drugs and/or diagnostic agent/agents - Google Patents

Chimeric constructs between cancer-homing peptides and cell-penetrating peptides coupled to anticancer drugs and/or diagnostic agent/agents Download PDF

Info

Publication number
WO2007108749A8
WO2007108749A8 PCT/SE2007/000268 SE2007000268W WO2007108749A8 WO 2007108749 A8 WO2007108749 A8 WO 2007108749A8 SE 2007000268 W SE2007000268 W SE 2007000268W WO 2007108749 A8 WO2007108749 A8 WO 2007108749A8
Authority
WO
WIPO (PCT)
Prior art keywords
cell
diagnostic agent
seq
cancer
peptides
Prior art date
Application number
PCT/SE2007/000268
Other languages
French (fr)
Other versions
WO2007108749A1 (en
Inventor
Uelo Langel
Helena Myrberg
Maarja Maee
Erkki Ruoslahti
Lianglin Zhang
Original Assignee
Cepep Iii Ab
Burnham Inst Medical Research
Uelo Langel
Helena Myrberg
Maarja Maee
Erkki Ruoslahti
Lianglin Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cepep Iii Ab, Burnham Inst Medical Research, Uelo Langel, Helena Myrberg, Maarja Maee, Erkki Ruoslahti, Lianglin Zhang filed Critical Cepep Iii Ab
Priority to AT07716076T priority Critical patent/ATE495197T1/en
Priority to EP07716076A priority patent/EP1991586B1/en
Priority to DE602007011901T priority patent/DE602007011901D1/en
Priority to US12/225,367 priority patent/US20100279918A1/en
Publication of WO2007108749A1 publication Critical patent/WO2007108749A1/en
Publication of WO2007108749A8 publication Critical patent/WO2007108749A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3 - SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/ or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described.
PCT/SE2007/000268 2006-03-20 2007-03-20 Chimeric constructs between cancer-homing peptides and cell-penetrating peptides coupled to anticancer drugs and/or diagnostic agent/agents WO2007108749A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AT07716076T ATE495197T1 (en) 2006-03-20 2007-03-20 CHIMERIC CONSTRUCTS BETWEEN CANCER-TARGING PEPTIDES AND CELL-PENETRATING PEPTIDES COUPLED TO ANTICANCER AGENT AND/OR DIAGNOSTIC AGENTS
EP07716076A EP1991586B1 (en) 2006-03-20 2007-03-20 Chimeric constructs between cancer-homing peptides and cell-penetrating peptides coupled to anticancer drugs and/or diagnostic agent/agents
DE602007011901T DE602007011901D1 (en) 2006-03-20 2007-03-20 PTIDES AND CELL PENETRATING PEPTIDES COUPLED A
US12/225,367 US20100279918A1 (en) 2006-03-20 2007-03-20 Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78339606P 2006-03-20 2006-03-20
US60/783,396 2006-03-20

Publications (2)

Publication Number Publication Date
WO2007108749A1 WO2007108749A1 (en) 2007-09-27
WO2007108749A8 true WO2007108749A8 (en) 2009-08-13

Family

ID=38522712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2007/000268 WO2007108749A1 (en) 2006-03-20 2007-03-20 Chimeric constructs between cancer-homing peptides and cell-penetrating peptides coupled to anticancer drugs and/or diagnostic agent/agents

Country Status (5)

Country Link
US (1) US20100279918A1 (en)
EP (1) EP1991586B1 (en)
AT (1) ATE495197T1 (en)
DE (1) DE602007011901D1 (en)
WO (1) WO2007108749A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101671B2 (en) 2007-01-03 2015-08-11 Sanford-Burnham Medical Research Institute Methods and compositions related to clot binding compounds
EP2250278B1 (en) * 2008-02-21 2023-04-05 Burnham Institute for Medical Research Methods and compositions related to peptides and proteins with c-terminal elements
JP5906184B2 (en) 2009-06-22 2016-04-20 バーナム インスティテュート フォー メディカル リサーチ Methods and compositions using peptides and proteins having C-terminal elements
WO2011020107A2 (en) * 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
US8912136B2 (en) 2009-12-18 2014-12-16 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
CA2800730C (en) * 2010-05-30 2019-06-11 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for antimicrobials
EP2576595B1 (en) * 2010-05-30 2016-12-21 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
EP2671597A1 (en) * 2012-06-07 2013-12-11 Cepep III AB Chimeric constructs between glioma-homing peptide and cell-penetrating peptides, gHoPe2
CN104780976B (en) 2012-08-13 2019-01-01 洛克菲勒大学 Treating and Diagnosing Melanoma
CN103981147B (en) 2013-02-08 2017-11-10 中国科学院上海生命科学研究院 A kind of new method for preparing hepatic parenchymal cells
WO2014147193A1 (en) * 2013-03-20 2014-09-25 Centre National De La Recherche Scientifique (Cnrs) New cell-penetrating peptide motifs
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
HRP20191254T1 (en) * 2014-05-21 2019-10-18 Entrada Therapeutics, Inc. PEPTIDES INPETING CELLS AND PROCEDURES FOR THEIR PRODUCTION AND USE
US10456443B2 (en) 2014-08-27 2019-10-29 Ohio State Innovation Foundation Peptidyl calcineurin inhibitors
WO2016172515A1 (en) 2015-04-23 2016-10-27 Sanford Burnham Prebys Medical Discovery Institute Targeted delivery system and methods of use therefor
AU2018209175B2 (en) 2017-01-17 2021-11-25 Michael David FORREST Therapeutic inhibitors of the reverse mode of ATP synthase
WO2018227112A1 (en) 2017-06-09 2018-12-13 The Trustees Of Columbia University In The City Of New York Short tat oligomers for drug delivery
CN111278810A (en) 2017-07-13 2020-06-12 迈克尔·大卫·福雷斯特 Therapeutic modulators of the reverse mode of ATP synthase
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
JP2021504315A (en) 2017-11-21 2021-02-15 ルジェニクス，インコーポレーテッド Polymorphs and their use
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC, CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RAILS
CN112386707B (en) * 2019-08-19 2023-08-11 辽宁医学诊疗科技研发中心有限公司 Tumor targeting polypeptide drug conjugate and preparation method thereof
CA3161274A1 (en) 2019-12-13 2021-06-17 Stephen Wald Metal salts and uses thereof
AU2021421391A1 (en) 2021-01-24 2023-07-20 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses
WO2024129459A1 (en) 2022-12-16 2024-06-20 University Of Rochester Repairmen! of barrier dysfunction in esophagus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US7488792B2 (en) * 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
WO2004106370A1 (en) * 2003-05-28 2004-12-09 Theraptosis Sa M11l derived peptides and therapeutic use thereof
JP2006526999A (en) * 2003-06-10 2006-11-30 トゥールゲン・インコーポレイテッド Transmissible DNA-binding protein
JP2009519033A (en) * 2005-12-16 2009-05-14 ディアト Cell penetrating peptide conjugates for delivering nucleic acids to cells

Also Published As

Publication number Publication date
WO2007108749A1 (en) 2007-09-27
EP1991586A1 (en) 2008-11-19
EP1991586B1 (en) 2011-01-12
DE602007011901D1 (en) 2011-02-24
US20100279918A1 (en) 2010-11-04
ATE495197T1 (en) 2011-01-15

Similar Documents

Publication Publication Date Title
WO2007108749A8 (en) Chimeric constructs between cancer-homing peptides and cell-penetrating peptides coupled to anticancer drugs and/or diagnostic agent/agents
EP2583976A3 (en) Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens
Ma et al. Peptide-drug conjugate: a novel drug design approach
EP2928907B1 (en) Cell penetrating peptides for intracellular delivery of molecules
ES2850726T3 (en) Cell penetrating peptides for intracellular delivery of molecules
EP2476697A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
WO2008063113A8 (en) Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf
HUP0300246A2 (en) Delivery system
MX2010002460A (en) Complexes of rna and cationic peptides for transfection and for immunostimulation.
EP1969000A2 (en) Cell penetrating peptides for intracellular delivery of molecules
UA100127C2 (en) Peptide cdh3 and drug containing it
Suk Choi et al. Cell penetrating peptides for tumor targeting
Yamaguchi et al. Identification of cyclic peptides for facilitation of transcellular transport of phages across intestinal epithelium in vitro and in vivo
US20150119340A1 (en) Fusion peptide and use thereof for cell membrane penetrating
WO2011048503A3 (en) Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof
Futami et al. Design of cytotoxic ribonucleases by cationization to enhance intracellular protein delivery
EP3219720A3 (en) Wdrpuh epitope peptides and vaccines containing the same
Maa et al. Peptide-Drug Conjugate: A Novel Drug Design Approach
Simonovic Synthesis and structure-activity relationship studies of marine-derived antimicrobial peptides and small cyclic peptidomimetics
Burlina et al. Modulation of the cellular uptake efficiency and the intracellular localization of conjugated Trojan peptides
Danalev et al. Synthesis of new hybrid cell penetrating peptides-medical drugs molecules
CZ200132A3 (en) Feeding system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07716076

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007716076

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12225367

Country of ref document: US